Ajay K. Singh, MBBS, FRCP, MBA
Articles by Ajay K. Singh, MBBS, FRCP, MBA
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
The benefit-risk ratio and considerations about unmet need are worth considering.
SGLT2i therapy is contraindicated in patients with type 1 diabetes mellitus (T1DM) who have CKD.
The first part of the dialysis moonshot is to prevent the need for dialysis.
Measuring eGFR and UACR is a key component of guideline-directed medical therapy for patients with CKD from type 2 diabetes.
The most important patients who should receive treatment with SGLT2 inhibitors are those with CKD and type 2 diabetes.
Editor's Note:
...
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.